Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

In response to the news of reported layoffs at the U.S. FDA over the weekend, Advanced Medical Association president and CEO ...

Once high-flying Bluebird Bio Inc. has found a way out of its financial squeeze, as funds managed by global investment firms ...

Though it’s been used off-label for more than three decades to treat cerebrotendinous xanthomatosis, Mirum Pharmaceuticals Inc.’s chenodiol gained an official U.S. FDA nod Feb. 21 as the first drug ...

Aptamers are single-stranded DNA or RNA molecules with unique 3D structures that allow for specific binding to a wide variety of ions and molecules. Due to their unique properties, aptamers have been ...

Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr ...

Approxima Srl raised €7.3 million (US$7.65 million) in the first close of its series A financing round for its tricuspid valve repair system which is based on reshaping the right ventricle.

Researchers from MBX Biosciences Inc. presented preclinical data on MBX-4291, a prodrug developed as a long-acting GLP-1/GIP co-agonist through MBX’s proprietary Precision Endocrine Peptide (PEP) ...

Ubiquitin-specific protease 7 (USP7) is involved in DNA repair and cell cycle progression and, due to its control over the ubiquitination of key proteins, may impact oncogenes like MDM2 and c-Myc, as ...

Duke Street Bio Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.

Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various ...